PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim(Royal National Orthopaedic Hospital), José Baselga(Harvard University), Patricia Cozar(University of North Carolina at Chapel Hill), María Teresa Calvo(University of North Carolina at Chapel Hill), Judit Grueso(University of North Carolina at Chapel Hill), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Isabel T. Rubio(Clinica Universidad de Navarra), Kristine Torres‐Lockhart(Albert Einstein College of Medicine), Olga Rodríguez(University of North Carolina at Chapel Hill), Javier Cortés(Villa Maria Hospital), Orland Dı́ez(Vall d'Hebron Hospital Universitari), Celina García-García(University of North Carolina at Chapel Hill), Lei He(Harvard University), Violeta Serra(Vall d'Hebron Institute of Oncology), José Pérez(University of North Carolina at Chapel Hill), Marta Guzmán(University of North Carolina at Chapel Hill), Aleix Prat(Hospital Clínic de Barcelona), Pilar Antón(University of North Carolina at Chapel Hill), Claudia Aura(University of North Carolina at Chapel Hill), Leif W. Ellisen(Harvard University), Maurizio Scaltriti(Harvard University)
Cited by 622
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|2.2k